ClearPoint Neuro, Inc. (CLPT) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped CLPT stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: ClearPoint Neuro, Inc. (NASDAQ: CLPT) occupies a critical niche at the intersection of medical robotics, intraoperative MRI navigation, and CNS-targeted biologic delivery. Despite recent headline pressure stemming from partner trial results and quarterly earnings volatility, CLPT presents a highly asymmetrical risk/reward profile. Supported by an estimated 55.7% top-line growth trajectory and a consensus Strong Buy rating pointing to over 160% implied upside, the company is positioning itself as an essential platform for gene and cell therapy delivery into the brain. While cash burn and reliance on third-party biopharma trial outcomes keep the downside tail wide (P5 at $5.20 in Year 1), successful transitions of partnered assets to commercial status could unlock transformative multi-bagger upside over the 5- to 10-year investment horizon. The saved 1-year distribution is P10 $6.8, P50 $15.5, and P90 $26.
Last analyzed · Model: gemini-3.8-flash
ClearPoint Neuro, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $6.8 | Pessimistic plausible scenario |
| P50 | $15.5 | Median scenario |
| P90 | $26 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
ClearPoint Neuro trades at an attractive entry valuation relative to its high-growth neuro-navigation and biologics delivery pipeline. Strong projected top-line revenue growth exceeding 50% and bullish analyst targets ($27.50–$30.00) provide significant upside impetus, though ongoing operational net losses, dilution risks, and binary exposure to partner clinical trials (such as uniQure's AMT-130) maintain elevated near-term volatility.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this CLPT analysis generated?
October 29, 2026.
Is this a guaranteed CLPT prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full CLPT stock analysis · CLPT sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.